Xichun Hu

21PUBLICATIONS
20CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|May 26, 2026
Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.

|Nov 20, 2025
Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.

Juan Jin, Tiantian Liu, Mengyuan Cai

|May 09, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu, Qingyuan Zhang, Tao Sun

|Mar 04, 2025
Ferroptosis-related genes as prognostic markers for survival and immunotherapy in triple-negative breast cancer: analysis of public databases and a single institution.

Yizhao Xie, Zhonghua Tao, Biyun Wang

|Feb 16, 2025
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Xichun Hu, Qingyuan Zhang, Leiping Wang

|Nov 18, 2024
Chaperonin-containing TCP1 subunit 6A inhibition via TRIM21-mediated K48-linked ubiquitination suppresses triple-negative breast cancer progression through the AKT signalling pathway.

Mengdi Yang, Jianing Cao, Tiantian Liu

Pageof 4

Frequent Collaborators

4 joint publications

Biyun Wang

3 joint publications

Zhonghua Tao

1 joint publications

Zhongyi Yang

1 joint publications

Dongmei Ji